{"id":447,"date":"2015-12-08T10:15:48","date_gmt":"2015-12-08T09:15:48","guid":{"rendered":"https:\/\/www.lungcancergroup.de\/en\/projekte\/"},"modified":"2016-03-09T10:28:21","modified_gmt":"2016-03-09T09:28:21","slug":"projects","status":"publish","type":"page","link":"https:\/\/www.lungcancergroup.de\/en\/projects\/","title":{"rendered":"Projects"},"content":{"rendered":"

[et_pb_section admin_label=”section”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Projekte” background_layout=”light” text_orientation=”left” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Projects<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Zeile” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” gutter_width=”3″ padding_mobile=”off” allow_player_pause=”off” parallax=”off” parallax_method=”off” make_equal=”off” parallax_1=”off” parallax_method_1=”off” padding_top_1=”23px” padding_right_1=”23px” padding_bottom_1=”23px” padding_left_1=”23px” parallax_2=”off” parallax_method_2=”off” padding_top_2=”23px” padding_right_2=”23px” padding_bottom_2=”23px” padding_left_2=”23px” parallax_3=”off” parallax_method_3=”off” padding_top_3=”23px” padding_right_3=”23px” padding_bottom_3=”23px” padding_left_3=”23px” column_padding_mobile=”on” module_class=”projektkacheln”][et_pb_column type=”1_3″][et_pb_image admin_label=”BMBF” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/BMBF.png” show_in_lightbox=”off” url=”http:\/\/www.ngfn.de\/en\/krebsgene.html” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

BMBF<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Funding by the Federal Ministry of Education and Research<\/strong> (BMBF) within the framework of the \u201cIntegrated Genome Research Network\u201d NGFNplus Program.<\/p>\n

Collaborative Project<\/h5>\n

Deciphering oncogene dependencies in human cancer oncogene mutation space (Coordinator: Roman Thomas).<\/p>\n

Subproject 3<\/h5>\n

Mutational analysis and its clinical implications in patients with lung cancer (J\u00fcrgen Wolf).<\/p>\n

Subproject 4<\/h5>\n

Systematic High-Throughput-Analysis of mutations in the development of tumors (Roman Thomas).<\/p>\n

\u2026 visit Website!<\/a><\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_3″][et_pb_image admin_label=”EU-Verbundprogramm” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/seventh.jpg” show_in_lightbox=”off” url=”http:\/\/www.curelung.eu\/index.html” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

EU 7th Framework Program<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Funding from the European Community (7th Framework) within the framework of the \u201cCurelung Lung Cancer Research\u201d project<\/p>\n

Project title<\/h5>\n

\u201cDetermining (epi)genetic therapeutic signatures for improving lung cancer prognosis\u201d<\/p>\n

\u2026 visit Website!<\/a><\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_3″][et_pb_image admin_label=”NRW PerMed Programm” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/nrw.jpg” show_in_lightbox=”off” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

NRW PerMed Program<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Ministerium f\u00fcr Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen
\n<\/strong>F\u00f6rderung durch das NRW-EU Ziel 2-Programm im Rahmen des \u201cEurop\u00e4ischen Fonds f\u00fcr regionale Entwicklung\u201d (EFRE).<\/p>\n

Verbundprojekt<\/h5>\n

Entwicklung von ZweitgenerationsTyrosinkinasehemmern und Diagnostik f\u00fcr die personalisierte Therapie von Patienten mit EGFR- und FGFR-abh\u00e4ngigen Tumoren (Koordinator Roman Thomas)<\/p>\n

Partner<\/h5>\n

Universit\u00e4t K\u00f6ln (Roman Thomas, Reinhard B\u00fcttner, J\u00fcrgen Wolf), Lead Discovery Center GmbH Dortmund, Technische Universit\u00e4t Dortmund<\/p>\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Zeile” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” gutter_width=”3″ padding_mobile=”off” allow_player_pause=”off” parallax=”off” parallax_method=”off” make_equal=”off” parallax_1=”off” parallax_method_1=”off” padding_top_1=”23px” padding_right_1=”23px” padding_bottom_1=”23px” padding_left_1=”23px” parallax_2=”off” parallax_method_2=”off” padding_top_2=”23px” padding_right_2=”23px” padding_bottom_2=”23px” padding_left_2=”23px” parallax_3=”off” parallax_method_3=”off” padding_top_3=”23px” padding_right_3=”23px” padding_bottom_3=”23px” padding_left_3=”23px” column_padding_mobile=”on” module_class=”projektkacheln”][et_pb_column type=”1_3″][et_pb_image admin_label=”Bayer Healthcare” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/bayer1.jpg” show_in_lightbox=”off” url=”\/studie\/select-1\/” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Bayer Healthcare<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Cooperation agreement to carry out an investigator-initiated phase I study (sponsored by LCGC ) to determine the \u201cRecommended Phase 2 Dose\u201d RP2D of sorafenib and everolimus with subsequent examination of the efficacy of the combination in KRAS mutant NSCLC patients (SORAVE-Study).<\/p>\n

\u2026 visit SORAVE-study!<\/a><\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_3″][et_pb_image admin_label=”Boehringer Ingelheim” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/boehringer.jpg” show_in_lightbox=”off” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Boehringer Ingelheim<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Cooperation agreement to carry out an investigator-initiated phase I study (sponsored by LCGC) to determine the \u201cRecommended Phase 2 Dose\u201d RP2D of BIBF 1120 and everolimus in patients with solid tumors.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_3″][et_pb_image admin_label=”Novartis” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/novertis.jpg” show_in_lightbox=”off” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Novartis<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Collaboration to establish an investigator-initiated phase II study (sponsored by LCGC) to evaluate the efficacy and safety of the combination of trastuzumab and AUY922 in the treatment of advanced non-small cell lung cancer with HER2 overexpression or amplification or mutation (TRY-Study).<\/p>\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Zeile” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” gutter_width=”3″ padding_mobile=”off” allow_player_pause=”off” parallax=”off” parallax_method=”off” make_equal=”off” parallax_1=”off” parallax_method_1=”off” padding_top_1=”23px” padding_right_1=”23px” padding_bottom_1=”23px” padding_left_1=”23px” parallax_2=”off” parallax_method_2=”off” padding_top_2=”23px” padding_right_2=”23px” padding_bottom_2=”23px” padding_left_2=”23px” parallax_3=”off” parallax_method_3=”off” padding_top_3=”23px” padding_right_3=”23px” padding_bottom_3=”23px” padding_left_3=”23px” column_padding_mobile=”on” module_class=”projektkacheln”][et_pb_column type=”1_3″][et_pb_image admin_label=”Pfizer” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/pfitzer.png” show_in_lightbox=”off” url=”http:\/\/gecp.org\/” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Pfizer<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Cooperation Agreement to carry out an investigator-initiated, multicenter phase II study (sponsored by LCGC) to determine the efficacy of the ALK\/ROS1 inhibitor crizotinib in NSCLC patients harbouring a ROS1 translocation in their tumor after firstline therapy (EUCROSS ) in collaboration with the Spanish Lung Cancer Group.<\/p>\n

\u2026 visit Website!<\/a><\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_3″][et_pb_image admin_label=”Roche” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/roche.jpg” show_in_lightbox=”off” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Roche<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

Cooperation agreement to carry out an investigator-initiated phase II study (sponsored by LCGC) for the evaluation of the early prediction of non-progression of non-small cell lung cancer during treatment with erlotinib and bevacizumab with fluorodeoxyglucose \u2013 F18 , F18- fluorothymidine and DCE \u2013 MRI.<\/p>\n

Cooperation to carry out an investigator-initiated phase II study (sponsored by LCGC) to evaluate the efficacy and safety of the combination of trastuzumab and AUY922 in the treatment of advanced non-small cell lung cancer with HER2 overexpression or amplification or mutation.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_3″][et_pb_image admin_label=”Bild” src=”https:\/\/www.lungcancergroup.de\/wp-content\/uploads\/2015\/12\/sfb832_logo_en.gif” show_in_lightbox=”off” url=”http:\/\/www.sfb832.de\/” url_new_window=”on” animation=”fade_in” sticky=”off” align=”center” force_fullwidth=”off” always_center_on_mobile=”on” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_css_main_element=”height:120px;”]
\n[\/et_pb_image][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

SFB 832<\/h3>\n

[\/et_pb_text][et_pb_toggle admin_label=”Umschalter” title=”Short description” open=”off” title_font_size=”16″ body_font_size=”13″ body_line_height=”1.5em” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n

The Special Research Center (SFB) 832 \u201cMolecular basis and modulation of cellular interactions in the tumor microenvironment \u201d is an interdisciplinary research network in the Cologne \u2013 Bonn area, funded by the German Research Foundation (DFG).
\nThe project A 6 is realized in collaboration with the LCGC.<\/p>\n

Project title<\/h5>\n

Combined use of chemical-genetic and imaging techniques to validate anti-angiogenic properties of anti-angiogenic compounds.<\/p>\n

Persons in charge<\/h5>\n

Roman Thomas, Roland Ulrich und J\u00fcrgen Wolf<\/p>\n

\u2026 visit Website!<\/a><\/p>\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Zeile”][et_pb_column type=”4_4″][et_pb_text admin_label=”Last Update” saved_tabs=”all” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_class=”content-update”]<\/p>\n

Last Update: March 09 2016 , 10:28<\/span><\/em><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Projects BMBF Funding by the Federal Ministry of Education and Research (BMBF) within the framework of the \u201cIntegrated Genome Research Network\u201d NGFNplus Program. Collaborative Project Deciphering oncogene dependencies in human cancer oncogene mutation space (Coordinator: Roman Thomas). Subproject 3 Mutational analysis and its clinical implications in patients with lung cancer (J\u00fcrgen Wolf). Subproject 4 Systematic […]<\/p>\n","protected":false},"author":19,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-447","page","type-page","status-publish","hentry"],"yoast_head":"\nProjects - Lung Cancer Group Cologne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lungcancergroup.de\/en\/projects\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Projects - Lung Cancer Group Cologne\" \/>\n<meta property=\"og:description\" content=\"Projects BMBF Funding by the Federal Ministry of Education and Research (BMBF) within the framework of the \u201cIntegrated Genome Research Network\u201d NGFNplus Program. Collaborative Project Deciphering oncogene dependencies in human cancer oncogene mutation space (Coordinator: Roman Thomas). Subproject 3 Mutational analysis and its clinical implications in patients with lung cancer (J\u00fcrgen Wolf). Subproject 4 Systematic […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lungcancergroup.de\/en\/projects\/\" \/>\n<meta property=\"og:site_name\" content=\"Lung Cancer Group Cologne\" \/>\n<meta property=\"article:modified_time\" content=\"2016-03-09T09:28:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/projects\/\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/projects\/\",\"name\":\"Projects - Lung Cancer Group Cologne\",\"isPartOf\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\"},\"datePublished\":\"2015-12-08T09:15:48+00:00\",\"dateModified\":\"2016-03-09T09:28:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/projects\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lungcancergroup.de\/en\/projects\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/projects\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.lungcancergroup.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/\",\"name\":\"Lung Cancer Group Cologne\",\"description\":\"Lungenkrebs Studiengruppe K\u00f6ln\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Projects - Lung Cancer Group Cologne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lungcancergroup.de\/en\/projects\/","og_locale":"en_US","og_type":"article","og_title":"Projects - Lung Cancer Group Cologne","og_description":"Projects BMBF Funding by the Federal Ministry of Education and Research (BMBF) within the framework of the \u201cIntegrated Genome Research Network\u201d NGFNplus Program. Collaborative Project Deciphering oncogene dependencies in human cancer oncogene mutation space (Coordinator: Roman Thomas). Subproject 3 Mutational analysis and its clinical implications in patients with lung cancer (J\u00fcrgen Wolf). Subproject 4 Systematic […]","og_url":"https:\/\/www.lungcancergroup.de\/en\/projects\/","og_site_name":"Lung Cancer Group Cologne","article_modified_time":"2016-03-09T09:28:21+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lungcancergroup.de\/en\/projects\/","url":"https:\/\/www.lungcancergroup.de\/en\/projects\/","name":"Projects - Lung Cancer Group Cologne","isPartOf":{"@id":"https:\/\/www.lungcancergroup.de\/en\/#website"},"datePublished":"2015-12-08T09:15:48+00:00","dateModified":"2016-03-09T09:28:21+00:00","breadcrumb":{"@id":"https:\/\/www.lungcancergroup.de\/en\/projects\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lungcancergroup.de\/en\/projects\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lungcancergroup.de\/en\/projects\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.lungcancergroup.de\/en\/"},{"@type":"ListItem","position":2,"name":"Projects"}]},{"@type":"WebSite","@id":"https:\/\/www.lungcancergroup.de\/en\/#website","url":"https:\/\/www.lungcancergroup.de\/en\/","name":"Lung Cancer Group Cologne","description":"Lungenkrebs Studiengruppe K\u00f6ln","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/pages\/447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/comments?post=447"}],"version-history":[{"count":1,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/pages\/447\/revisions"}],"predecessor-version":[{"id":1249,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/pages\/447\/revisions\/1249"}],"wp:attachment":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/media?parent=447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}